Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Dec / FDA or EMA Novel Drug Approvals 2024: Anagrams Edition
Manufacture Advanced Medicine Bioprocessing - Single Use Systems Small Molecules Standards & Regulation Bioprocessing Biopharma Small Molecules Regulation & Standards Business & Trends

FDA or EMA Novel Drug Approvals 2024: Anagrams Edition

So you know your small molecule from your AAV, but can you unscramble the names of these 2024 novel drug approvals?

By Rob Coker 12/24/2024 1 min read

Share

It’s Christmas: a time for fun and games! Below you will find a list of 14 anagrams of drug names approved for human use in 2024 by either the US FDA or the European Medicines Agency (Nemluvio, Balversa, Ordspono, Elevidys, Adstriladrin, Ojemda, Xolremdi, Tevimbra, Imdelltra, Niktimvo, Winrevair, Anktiva, Alhemo, Exblifep). Can you match them all without cheating? Let me know how you get on: rob.coker@conexiant.com

  1. Vomit kin
  2. In volume 
  3. Mild later 
  4. Older mix 
  5. Doe jam 
  6. Via tank 
  7. Rin waiver 
  8. Brave Tim 
  9. Px belief 
  10. Spoon Rod 
  11. A holme 
  12. Lab raves 
  13. Trials and ID 
  14. Idle vyes 

Answers:

  1. Niktimvo 
  2. Nemluvio
  3. Imdelltra
  4. Xolremdi
  5. Ojemda
  6. Anktiva
  7. Winrevair
  8. Tevimbra
  9. Exblifep
  10. Ordspono
  11. Alhemo
  12. Balversa
  13. Adstriladrin 
  14. Elevidys 

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.